Name reflects vertically-aligned healthcare ecosystem business model integrating data captured via telemedicine, online pharmacy, lab tests and wearables to perfect patients&#39; digital health twins in the Health Lives

<ul style="list-style-type:disc;"><li>Name reflects vertically-aligned healthcare ecosystem business model integrating data captured via telemedicine, online pharmacy, lab tests and wearables to perfect patients' digital health twins in the Health Lives Here app designed to influence/optimize behavior</li><li>EinsteinRx AI&#8482; capabilities expanding into medical, laboratory and wearables fields</li><li>Pharmacy and Pharmacy Services division being rebranded as Corexa Health&#8482;</li><li>Company positioned to empower patients to seize ownership of their health data with blockchain-enabled data management to control data and participate in its monetization</li><li>(1) 2,647,198 common shares outstanding, with (2) 1,333,930 of those shares locked up for at least ninety (90) days from today, and (3) 919,465 common shares deposited in DTCC, leaving (4) 80,628 cash warrants with fixed $35.00 exercise price representing only other securities currently eligible for deposit into DTCC for free trading shares</li></ul> TAMPA, FL / <a href='https://www.accessnewswire.com/'>ACCESS Newswire</a> / June 26, 2026 / Wellgistics Health, Inc. ("Wellgistics") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/WGRX">WGRX</a>), a Health IT leader, integrating pharmacy dispensing AI platform EinsteinRx&#8482; into patented pharmacy smart contracts platform PharmacyChain&#8482;, today announced that its management and Board of Directors has selected DataMeds AI, Inc as its new corporate name, subject to shareholder approval. The proposed new stock sticker remains MEDS. A preliminary proxy was filed on Thursday, June 18, 2026 with the U.S. Securities & Exchange Commission requesting shareholder approval to effect the name change. The DataMeds AI, Inc. name was advanced to replace the name DelivMeds AI, Inc. that was previously announced as the projected Wellgistics Health, Inc. corporate name. Concurrent with this announcement, Wellgistics also announced that it is changing the name of its Pharmacy and Pharmacy Services division to Corexa Health."As we continue to pursue the previously announced proposed transaction with DataVault AI, Scilex Pharma, EOS Holdings, and HealthBridge Advisors while also beginning to integrate the operations of the new business lines being consolidated within the existing Wellgistics Health public vehicle, we believe strongly that the name DataMeds AI captures the essence of the significant, but necessary task we are taking on," said Gerald E. Commissiong, Interim Co-CEO of Wellgistics Health. "We are working to create the digital platform that empowers and rewards patients who opt-in to consolidate their health data within the Health Lives Here app by expanding our EinsteinRx AI technology into adjacent medical areas so that providers are armed more comprehensive information to timely make better decisions that will the patient not only with better health, but also allow for patient-centric revenue participation opportunities that result from the commerce of their health data. We intend to empower patients to seize ownership of their health information so that we can break down the data sharing barriers that exist in healthcare today that stifle forward progress."Wellgistics confirms that as of the date of this press release there are 2,647,198 common shares outstanding. Certain stockholders holding approximately1,333,930 common shares, representing a majority of the outstanding common shares, have entered into lock-up agreements that preclude the sale of their shares into the market for at least ninety (90) days from today's date. There are currently 919,465 shares of Wellgistics common stock deposited in Depository Trust & Clearing Corporation available for trading. There are no debt or preferred equity securities of the Company that are eligible to convert into free trading common shares at the current time. There is a total of 80,826 cash warrants outstanding, each with a fixed exercise price of $35.00 per share, that are currently eligible to be exercised into free trading common shares. Investors should refer to the Company's filings with the Securities and Exchange Commission for additional information regarding the Company's capitalization and outstanding securities. The Board is evaluating the previously announced Dream Bowl 2026 Meme Coin Token distribution and expects to provide additional information, if any, at an appropriate time.About Wellgistics Health, Inc.Wellgistics Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/WGRX">WGRX</a>) is a Health IT leader integrating its proprietary pharmacy dispensing optimization artificial intelligence platform EinsteinRx&#8482; into its blockchain-enabled smart contracts platform PharmacyChain&#8482; to optimize the prescription drug dispensing journey. Its integrated platform connects more than 6,500 pharmacies and 200+ manufacturers, offering wholesale distribution, digital prescription routing, direct-to-patient delivery, and AI-powered hub services such as eligibility verification, onboarding, adherence support, prior authorization, and cash-pay fulfillment designed to improve patient access and transparency across the prescription ecosystem.Wellgistics Health recently entered into a fully binding letter of intent with DataVault AI, Inc., EOS Technology Holdings, Inc., Scilex Holdings, Inc. and HealthBridge Advisors LLC to form DataMeds AI. DataMeds AI intends to focus on the vertical integration of technology, pharmacy, pharmaceutical-adjacent and telemedicine business units to deliver a better healthcare experience for consumers. Tollo Health, the operating company whose control is being contributed to DataMeds AI by HealthBridge Advisors, has a pending partnership with NFL Alumni Health to advance the Health Lives Here app that will become the centerpiece of DataMeds AI direct-to-consumer marketing efforts. The parties currently anticipate completing the proposed transaction during the third quarter of 2026, subject to the satisfaction or waiver of customary closing conditions and other applicable approvals. There can be no assurance that the transaction will be completed on the anticipated terms or timetable, or at all.For more information, visit <a rel="nofollow" href="https://pr.report/n1kp">www.wellgisticshealth.com</a>.Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, without limitation, statements regarding the proposed corporate name change to DataMeds AI, Inc.; the proposed rebranding of the Company's Pharmacy and Pharmacy Services division as Corexa Health; the Company's proposed transaction with DataVault AI Inc., Scilex Holding Company, EOS Holdings and HealthBridge Advisors; the anticipated timing, structure, terms and completion of such transaction; the satisfaction or waiver of closing conditions; the receipt of stockholder approval and any other required approvals; the Company's anticipated business strategy, operating plans and growth opportunities; the integration of telemedicine, pharmacy, laboratory, wearable-device, artificial intelligence, blockchain and data-management technologies; the proposed development, commercialization and expansion of EinsteinRx AI, PharmacyChain, Health Lives Here and related platforms; the Company's ability to empower patients to access, manage, control or monetize health data; the anticipated benefits of the Company's technology platforms, strategic relationships and business combinations; the Company's capitalization, outstanding securities, lock-up arrangements, public float and registration statements; the Company's ability to maintain compliance with Nasdaq listing standards; and the Company's liquidity, capital resources and ability to fund operations.Forward-looking statements are based on current expectations, estimates, projections and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, among others, the risk that the proposed name change may not be approved by stockholders or otherwise completed; the risk that the proposed transaction may not be completed on the anticipated terms or timeline, or at all; the risk that closing conditions may not be satisfied or waived; risks related to integrating multiple businesses, technologies and platforms; risks related to the development, commercialization, adoption, scalability and regulatory treatment of artificial intelligence, blockchain-enabled data management, telemedicine, pharmacy, laboratory, wearable-device and digital health technologies; risks related to healthcare privacy, cybersecurity, data ownership, data monetization and compliance with applicable healthcare, pharmacy, consumer protection, data protection and securities laws; risks related to the Company's liquidity, capital resources, indebtedness, dilution, outstanding securities, registration statements and ability to raise additional capital; risks related to maintaining compliance with Nasdaq listing standards; market, regulatory, competitive and operational risks affecting the healthcare, pharmacy, pharmaceutical distribution, artificial intelligence, technology and digital asset sectors; and other risks described in the Company's filings with the Securities and Exchange Commission.Forward-looking statements speak only as of the date of this press release. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.Wellgistics Media & Investor Contact Media: <a rel="nofollow" href="mailto:media@wellgisticshealth.com">media@wellgisticshealth.com</a> Investor Relations: <a rel="nofollow" href="mailto:IR@wellgisticshealth.com">IR@wellgisticshealth.com</a>SOURCE: Wellgistics Health, Inc. View the original <a href='https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/datameds-ai-inc.-selected-as-proposed-new-name-for-wellgistics-health-1182826'>press release</a> on ACCESS Newswire 
 <img src="https://app.accessnewswire.com/img.ashx?id=1182826" width="0" height="0"/>

WGRX

DataMeds AI, Inc. Selected as Proposed New Name for Wellgistics Health, Inc.

Wellgistics Health to rename DataMeds AI with MEDS ticker in major corporate move

<section class="insight" data-version="1">
 <section data-block="information">
 <h3>Information</h3>
 Name reflects vertically-aligned healthcare ecosystem business model integrating data captured via telemedicine, online pharmacy, lab tests and wearables to perfect patients&amp;#39; digital health twins in the Health Lives
 </section>

 <section data-block="ai-summary-paragraph">
 <h3>AI Summary</h3>
 Wellgistics Health, trading as WGRX, announced a corporate name change to DataMeds AI, Inc. and rebranding of its Pharmacy division to Corexa Health, as it pursues a planned DataMeds AI merger with DataVault AI, Scilex, EOS Holdings, and HealthBridge Advisors. A Q3 2026 closing target and insider lock-ups could constrain near-term supply and potential upside.
 </section>

 <section data-block="ai-summary-bullets">
 <h3>Key Points</h3>
 <ul><li>Wellgistics Health to rename DataMeds AI, Inc.; ticker MEDS pending shareholder approval.</li><li>Pharmacy division rebranded as Corexa Health, aligning with digital health strategy.</li><li>Proposed DataMeds AI merger with DataVault AI, Scilex, EOS, HealthBridge; target Q3 2026.</li><li>EinsteinRx AI expands into medical labs and wearables; Health Lives Here app monetizes data.</li><li>Share count: 2.65M outstanding; 1.33M locked 90 days; 919k DTCC; 80k warrants.</li></ul>
 </section>

 <section data-block="companies-mentioned">
 <h3>Companies Mentioned</h3>
 <ul><li>Wellgistics Health, Inc. (WGRX): Subject to name change; MEDS ticker planned; potential Corexa Health branding; strategic reorganization.</li><li>DataMeds AI, Inc. (MEDS): New corporate name; likely new primary listing; potential higher visibility.</li><li>Scilex Holding Company (SCLX): Participating in proposed DataMeds AI transaction; potential synergies.</li><li>DataVault AI, Inc. (N/A): Proposed transaction partner; terms not disclosed.</li><li>NFL Alumni Health (N/A): Tollo Health partnership; Health Lives Here app anchor.</li></ul>
 </section>

 <section data-block="category">
 <h3>Corporate Developments</h3>
 Category: Corporate Developments. The article centers on a name change, rebranding, and a multi-party M&amp;A-like transaction, signaling potential near-term stock volatility and longer-term value if the DataMeds AI platform achieves scale and data monetization.
 </section>

 <section data-block="market-moving">
 <h3>Market-Moving</h3>
 <ul><li>Name change to MEDS and ticker transition could alter liquidity.</li><li>Q3 2026 deal closing timeline is primary price catalyst.</li><li>Insider lock-ups limit near-term float, suppressing selling pressure.</li><li>80k warrants at $35 could cap upside until warrants exercise.</li></ul>
 </section>

 <section data-block="key-facts">
 <h3>Key Facts</h3>
 <ul><li>Shares outstanding: 2,647,198.</li><li>Locked-up shares: 1,333,930 (≥90 days).</li><li>DTCC shares deposited: 919,465.</li><li>Cash warrants outstanding: 80,826 with $35 strike.</li><li>Closing target: Q3 2026 for DataMeds AI deal.</li></ul>
 </section>

 <section data-block="trading-thesis">
 <h3>Trading Thesis</h3>
 Near-term, WGRX may drift as the name/ticker transition plays out; upside possible on Q3 2026 deal closure.
 </section>
</section>


<ul style="list-style-type:disc;"><li>Name reflects vertically-aligned healthcare ecosystem business model integrating data captured via telemedicine, online pharmacy, lab tests and wearables to perfect patients' digital health twins in the Health Lives Here app designed to influence/optimize behavior</li><li>EinsteinRx AI&#8482; capabilities expanding into medical, laboratory and wearables fields</li><li>Pharmacy and Pharmacy Services division being rebranded as Corexa Health&#8482;</li><li>Company positioned to empower patients to seize ownership of their health data with blockchain-enabled data management to control data and participate in its monetization</li><li>(1) 2,647,198 common shares outstanding, with (2) 1,333,930 of those shares locked up for at least ninety (90) days from today, and (3) 919,465 common shares deposited in DTCC, leaving (4) 80,628 cash warrants with fixed $35.00 exercise price representing only other securities currently eligible for deposit into DTCC for free trading shares</li></ul> TAMPA, FL / <a href='https://www.accessnewswire.com/'>ACCESS Newswire</a> / June 26, 2026 / Wellgistics Health, Inc. ("Wellgistics") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/WGRX">WGRX</a>), a Health IT leader, integrating pharmacy dispensing AI platform EinsteinRx&#8482; into patented pharmacy smart contracts platform PharmacyChain&#8482;, today announced that its management and Board of Directors has selected DataMeds AI, Inc as its new corporate name, subject to shareholder approval. The proposed new stock sticker remains MEDS. A preliminary proxy was filed on Thursday, June 18, 2026 with the U.S. Securities & Exchange Commission requesting shareholder approval to effect the name change. The DataMeds AI, Inc. name was advanced to replace the name DelivMeds AI, Inc. that was previously announced as the projected Wellgistics Health, Inc. corporate name. Concurrent with this announcement, Wellgistics also announced that it is changing the name of its Pharmacy and Pharmacy Services division to Corexa Health."As we continue to pursue the previously announced proposed transaction with DataVault AI, Scilex Pharma, EOS Holdings, and HealthBridge Advisors while also beginning to integrate the operations of the new business lines being consolidated within the existing Wellgistics Health public vehicle, we believe strongly that the name DataMeds AI captures the essence of the significant, but necessary task we are taking on," said Gerald E. Commissiong, Interim Co-CEO of Wellgistics Health. "We are working to create the digital platform that empowers and rewards patients who opt-in to consolidate their health data within the Health Lives Here app by expanding our EinsteinRx AI technology into adjacent medical areas so that providers are armed more comprehensive information to timely make better decisions that will the patient not only with better health, but also allow for patient-centric revenue participation opportunities that result from the commerce of their health data. We intend to empower patients to seize ownership of their health information so that we can break down the data sharing barriers that exist in healthcare today that stifle forward progress."Wellgistics confirms that as of the date of this press release there are 2,647,198 common shares outstanding. Certain stockholders holding approximately1,333,930 common shares, representing a majority of the outstanding common shares, have entered into lock-up agreements that preclude the sale of their shares into the market for at least ninety (90) days from today's date. There are currently 919,465 shares of Wellgistics common stock deposited in Depository Trust & Clearing Corporation available for trading. There are no debt or preferred equity securities of the Company that are eligible to convert into free trading common shares at the current time. There is a total of 80,826 cash warrants outstanding, each with a fixed exercise price of $35.00 per share, that are currently eligible to be exercised into free trading common shares. Investors should refer to the Company's filings with the Securities and Exchange Commission for additional information regarding the Company's capitalization and outstanding securities. The Board is evaluating the previously announced Dream Bowl 2026 Meme Coin Token distribution and expects to provide additional information, if any, at an appropriate time.About Wellgistics Health, Inc.Wellgistics Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/WGRX">WGRX</a>) is a Health IT leader integrating its proprietary pharmacy dispensing optimization artificial intelligence platform EinsteinRx&#8482; into its blockchain-enabled smart contracts platform PharmacyChain&#8482; to optimize the prescription drug dispensing journey. Its integrated platform connects more than 6,500 pharmacies and 200+ manufacturers, offering wholesale distribution, digital prescription routing, direct-to-patient delivery, and AI-powered hub services such as eligibility verification, onboarding, adherence support, prior authorization, and cash-pay fulfillment designed to improve patient access and transparency across the prescription ecosystem.Wellgistics Health recently entered into a fully binding letter of intent with DataVault AI, Inc., EOS Technology Holdings, Inc., Scilex Holdings, Inc. and HealthBridge Advisors LLC to form DataMeds AI. DataMeds AI intends to focus on the vertical integration of technology, pharmacy, pharmaceutical-adjacent and telemedicine business units to deliver a better healthcare experience for consumers. Tollo Health, the operating company whose control is being contributed to DataMeds AI by HealthBridge Advisors, has a pending partnership with NFL Alumni Health to advance the Health Lives Here app that will become the centerpiece of DataMeds AI direct-to-consumer marketing efforts. The parties currently anticipate completing the proposed transaction during the third quarter of 2026, subject to the satisfaction or waiver of customary closing conditions and other applicable approvals. There can be no assurance that the transaction will be completed on the anticipated terms or timetable, or at all.For more information, visit <a rel="nofollow" href="https://pr.report/n1kp">www.wellgisticshealth.com</a>.Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, without limitation, statements regarding the proposed corporate name change to DataMeds AI, Inc.; the proposed rebranding of the Company's Pharmacy and Pharmacy Services division as Corexa Health; the Company's proposed transaction with DataVault AI Inc., Scilex Holding Company, EOS Holdings and HealthBridge Advisors; the anticipated timing, structure, terms and completion of such transaction; the satisfaction or waiver of closing conditions; the receipt of stockholder approval and any other required approvals; the Company's anticipated business strategy, operating plans and growth opportunities; the integration of telemedicine, pharmacy, laboratory, wearable-device, artificial intelligence, blockchain and data-management technologies; the proposed development, commercialization and expansion of EinsteinRx AI, PharmacyChain, Health Lives Here and related platforms; the Company's ability to empower patients to access, manage, control or monetize health data; the anticipated benefits of the Company's technology platforms, strategic relationships and business combinations; the Company's capitalization, outstanding securities, lock-up arrangements, public float and registration statements; the Company's ability to maintain compliance with Nasdaq listing standards; and the Company's liquidity, capital resources and ability to fund operations.Forward-looking statements are based on current expectations, estimates, projections and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, among others, the risk that the proposed name change may not be approved by stockholders or otherwise completed; the risk that the proposed transaction may not be completed on the anticipated terms or timeline, or at all; the risk that closing conditions may not be satisfied or waived; risks related to integrating multiple businesses, technologies and platforms; risks related to the development, commercialization, adoption, scalability and regulatory treatment of artificial intelligence, blockchain-enabled data management, telemedicine, pharmacy, laboratory, wearable-device and digital health technologies; risks related to healthcare privacy, cybersecurity, data ownership, data monetization and compliance with applicable healthcare, pharmacy, consumer protection, data protection and securities laws; risks related to the Company's liquidity, capital resources, indebtedness, dilution, outstanding securities, registration statements and ability to raise additional capital; risks related to maintaining compliance with Nasdaq listing standards; market, regulatory, competitive and operational risks affecting the healthcare, pharmacy, pharmaceutical distribution, artificial intelligence, technology and digital asset sectors; and other risks described in the Company's filings with the Securities and Exchange Commission.Forward-looking statements speak only as of the date of this press release. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.Wellgistics Media & Investor Contact Media: <a rel="nofollow" href="mailto:media@wellgisticshealth.com">media@wellgisticshealth.com</a> Investor Relations: <a rel="nofollow" href="mailto:IR@wellgisticshealth.com">IR@wellgisticshealth.com</a>SOURCE: Wellgistics Health, Inc. View the original <a href='https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/datameds-ai-inc.-selected-as-proposed-new-name-for-wellgistics-health-1182826'>press release</a> on ACCESS Newswire 
 <img src="https://app.accessnewswire.com/img.ashx?id=1182826" width="0" height="0"/>

Wellgistics Health, trading as WGRX, announced a corporate name change to DataMeds AI, Inc. and rebranding of its Pharmacy division to Corexa Health, as it pursues a planned DataMeds AI merger with DataVault AI, Scilex, EOS Holdings, and HealthBridge Advisors. A Q3 2026 closing target and insider lock-ups could constrain near-term supply and potential upside.

DataMeds AI, Inc. Selected as Proposed New Name for Wellgistics Health, Inc.

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Corporate Developments

Related News